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- AC9 is a trans-membrane adenylyl cyclase highly expressed in the brain and 
the heart. 
- The response of AC9 to the activation of Gs-coupled receptors (GsCR) is low. 
- A stretch of nine AA-residues in the COOH-tail of AC9 blunts the response to 
GsCR. 
- COOH-terminally cleaved AC9 was detected in rodent and human heart. 
- Proteases may gate the activation of AC9 by cleaving the auto-inhibitory 
COOH-tail. 
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ABSTRACT 
 
Trans-membrane adenylyl cyclase (tmAC) isoforms show markedly distinct 
regulatory properties that have not been fully explored. AC9 is highly expressed in 
vital organs such as the heart and the brain. Here, we report that the isoform-specific 
carboxyl-terminal domain (C2b) of AC9 inhibits the activation of the enzyme by Gs-
coupled receptors (GsCR).  In human embryonic kidney cells (HEK293) stably 
overexpressing AC9, cAMP production by AC9 induced upon the activation of 
endogenous -adrenergic and prostanoid GsCRs was barely discernible. Cells 
expressing AC9 lacking the C2b domain showed a markedly enhanced cAMP 
response to GsCR. Subsequent studies of the response of AC9 mutants to the 
activation of GsCR revealed that residues 1268-1276 in the C2b domain were critical 
for auto-inhibition. Two main species of AC9 of 130K and ≥170K apparent molecular 
weight were observed on immunoblots of rodent and human myocardial membranes 
with NH2-terminally directed anti-AC9 antibodies. The lower molecular weight AC9 
band did not react with antibodies directed against the C2b domain. It was the 
predominant species of AC9 in rodent heart tissue and some of the human samples. 
There is a single gene for AC9 in vertebrates, moreover, amino acids 957-1353 of 
the COOH-terminus are encoded by a single exon with no apparent signs of mRNA 
splicing or editing making it highly unlikely that COOH-terminally truncated AC9 could 
arise through the processing or editing of mRNA. Thus, deductive reasoning leads to 
the suggestion that proteolytic cleavage of the C2b auto-inhibitory domain may 
govern the activation of AC9 by GsCR. 
 
Key words: auto-inhibition; adenylyl cyclase, cyclic AMP, myocardium; limited 
proteolysis; heart failure. 
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1. INTRODUCTION 
 
Trans-membrane adenylyl cyclases (tmAC) are integral membrane proteins that 
produce the ubiquitous intracellular messenger adenosine 3’5’ monophosphate 
(cAMP) from ATP.  Similar to other intracellular signalling proteins, tmAC are 
produced from a family of genes giving rise to nine isoforms of tmAC with distinct 
regulatory properties [1-3].  However, knowledge about the exact function and 
biological significance of the isoform specific regulation in tmAC is far from complete 
[3, 4].  The schematic structure of tmAC is shown in Fig.1A. The catalytic core of the 
enzyme is formed through non-covalent interactions between the C1a and C2a 
cytoplasmic domains [5].  The primary amino acid sequence of these domains is 
relatively well-conserved between paralogues of tmAC. In contrast, the NH2-terminal 
domain, the trans-membrane domains, as well as the cytoplasmic C1b and C2b 
domains show low sequence homology between the isoforms [2, 3].  In turn, the 
isoform-specific sequences show minimal interspecies variation in vertebrates, 
indicating that the isoform-specific facets of tmAC function are governed by these 
parts of the protein. The present study analysed the contribution of the C2b domain 
to the regulatory properties of trans-membrane adenylyl cyclase 9 (AC9) [6].  First, 
this focus was prompted by the wide variation in the size of the C2b domain – in AC2 
it consists of about 11 amino acid residues whereas in AC9 it is 111. Second, a 
considerable number of studies have been reported with a human AC9 clone 
(dfm_AC9), [3, 7, 8] that has a double frame-shift mutation close to the start of the 
C2b domain (Fig 1 A and C). As a result, the C2B domain of dfm_AC9 is shorter, and 
of different primary sequence than that of AC9 (Fig 1C). Thus, it was of interest to 
compare the properties of what appears to be the physiological version of the 
enzyme with those of this mutant. While basal cAMP production by AC9 could be 
readily analysed in HEK293 cells stably expressing mouse [9] or human AC9 [10] the 
activation of the enzyme by GsCR in these cells was poor. A similar observation has 
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 4 
been published by Rhee et al [11] using COS 7 cells as the in transfecto context. We 
now report the identification of a short motif in the C2b domain of AC9 occupying 
positions 1268-1276 in the protein chain, that suppresses the activation of the 
enzyme by receptor-activated Gs.  Moreover, we provide evidence that AC9 is 
subject to limited COOH-terminal proteolysis in the heart indicating that auto-
inhibition by the C2b domain is a relevant mechanism of biological control.  
 
2.  MATERIALS AND METHODS 
 
2.1 Site-directed mutagenesis  
The human AC9 cDNA previously reported [10] was subcloned into pcDNA3.1 
(Invitrogen).  Mutations were introduced by site-directed mutagenesis with custom-
designed primers using Phusion High-Fidelity DNA Polymerase (Thermo Fisher 
Scientific Waltham, MA USA) as per the manufacturer’s instructions.  The resulting 
constructs were verified by DNA sequencing of the entire coding region (Biomi Ltd, 
Gödöllő, Hungary). COOH-terminally truncated AC9 versions are indexed by the 
single letter code of last amino acid and its position before the stop codon.  For 
example, AC9_Y1242 is the version truncated at the junction of the C2a and C2b 
domains. The primary sequence of the COOH-terminal from position 1240 is shown 
in Fig 1B.  
 
 
 
 
2.2 Cell culture  
Stable human embryonic kidney cell (HEK 293) lines obtained upon transfection 
using Metafectene Pro (Biontex Laboratories GmbH) with cDNAs encoding human 
AC9, AC9 ending at residue Y1242 (AC9_1242) or the skeleton vector pcDNA3.1 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 5 
were maintained under antibiotic selection using neomycin (0.6 mg/ml), in Dulbecco’s 
MEM supplemented with 10 v/v% fetal bovine serum.  These cells were pated on 96-
well culture plates (Greiner Hungary Ltd, Mosonmagyaróvár, Hungary) at a density of 
5 x 104 cells/ well and used 48h later to analyse the cAMP response to isoproterenol 
and PGE2.  
 
 A HEK293 cell line stably expressing 5-HT7A receptors (
3H-SB269970 binding 
capacity for crude membrane protein: 20±3 pmol/mg protein, mean ±S.E.M. n=4) 
was also produced and maintained under neomycin selection. These cells were 
transiently transfected by the calcium-phosphate method [12] with the expression 
vectors of the requisite wild-type and variously mutated AC9 cDNAs. Forty-eight h 
after transfection, the cells were detached from the culture dishes with Ca2+-, Mg2+-
free HBSS (Sigma H 6648) supplemented with 3 mM Na2EDTA (pH 8), pelleted by 
cenrifugation at  800 x g for 10min, resuspended and replated at a density of 105 
cells/well in flat-bottom 96-well plates  coated with poly-L-lysine (Sigma SIAL0596 ). 
The cells were used 24 h later to analyse the cAMP response to 5-HT.  The rest of 
the cells (5 x 106 /transfection), was plated on 150 mm diameter round tissue culture 
plates and collected at 72h after transfection for ligand binding assay and the 
subsequent analysis of AC9 expression by immunoblots. In some experiments, 
COS7 cells were subjected to the same transfection regime, except that a pcDNA3.1 
based expression plasmid for the human 5-HT7A receptor was co-transfected with 
AC9.   At least two independent transfections were carried out for each AC9 mutant 
tested in this study.  
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2.3 Assay of cAMP production 
 The culture medium was removed, and HAM’s F10 medium was added (100 μl/well, 
Gibco, 31550-031). The cells were incubated for 2.5 h at 37°C in a tissue culture 
incubator in an atmosphere of 95%O2-5% CO2. Subsequently, the cells were washed 
once with warm HBSS supplemented with 10 mM HEPES, pH 7.4 and incubated in 
100µl of the same medium at 37°C. After 20 min, 50 µl fresh medium was added 
supplemented with 2 mM isobutylmethylxanthine (Sigma, I5879 ) and the cells were 
incubated at 37°C in a total volume of 150 µl.  Fifteen minutes later, 50 µl of agonist 
solution were added and the incubation was continued at 37°C, for various time 
intervals. The incubation was terminated by the addition of 50 µl of ice-cold 0.5 M 
HCl. In agonist concentration-response studies the incubation of the wells was 
uniformly terminated at 15 min as by that time the cAMP concentration of the cells 
plus medium reached a steady-state plateau. In some cases, the assay was carried 
out under Ca2+-depleting conditions [9, 13], with no added Ca2+, 1mM EGTA and 1 
µM ionomycin (Sigma,  I9657) introduced at the addition HBSS.  Upon the 
termination of the incubation, the concentration of cAMP in the wells was quantified 
by radioimmunoassay [13]. 
 
2.4 Ligand-binding assay for 5-HT7A receptors  
Frozen pellets of HEK293 cells stably expressing 5-HT7A receptors were 
resuspended in homogenization buffer (50 mM HEPES buffer with 27% Sucrose, 5 
mM EDTA, pH 7.5) and rapidly refrozen for 30 min at -80 °C. After thawing, the cells 
were homogenized for 30 sec at setting 7 with a T-25 IKA Ultraturrax homogenizer 
and centrifuged for 5 min at 300 x g, 4°C. The supernatant was centrifuged 20 min at 
27,000 x g, 4 °C. The pellet was resuspended in 50 mM HEPES buffer supplemented 
1 mM EDTA, pH 7.5.  Centrifugation and resuspension were repeated once more. 
The crude membranes were diluted in the binding reaction buffer (50 mM Tris-HCl, 
10 mM MgSO4, 0,5 mM EDTA, pH 7.5) and incubated with 
3H-SB-269970 (New 
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 7 
England Nuclear) for 120 min at room temperature. The bound and the free tracer 
fractions were separated by filtration over Whatman GF/C filters presoaked in 0.3% 
(w/v) polyethyleneimine. After copious washing with buffer (50 mM Tris-HCl, 10 mM 
MgSO4, 0,5 mM EDTA, pH 7.5) the filters were dried and the amount of radioactivity 
attached to the filters was quantified by liquid scintillation counting in a Perkin-Elmer 
Top-Count NXT or Packard Tri-Carb 2900TR instrument. Ligand-binding curves were 
fitted by non-linear regression using Graphpad Prism v. 6.0 and Kd and Bmax values 
were calculated with the “one site – specific binding” equation.  
 
2.5 Immunocytochemistry  
HEK293 cells stably expressing WT human AC9 and AC9_Y1242 were plated on 
poly-D-lysine-coated coverslips and cultured as described above.  Two to four days 
after plating, the coverslips were briefly washed with phosphate-buffered saline 
(PBS) and exposed to Zamboni’s fixative, pH 7.4, for 20 min at 4°C.  Following 
fixation the cells were processed for immunostaining as previously reported [10]. 
Primary antibodies: affinity-purified rabbit antibodies (1:1000) raised against the NH2-
terminal region and affinity purified sheep antibodies (1:1000) against the COOH-
terminus of human AC9 [9]. Secondary antibodies: Alexa fluor 488-conjugated 
donkey anti-rabbit IgG (Invitrogen A21206) and Alexa fluor 594-conjugated donkey 
anti-sheep IgG (Invitrogen A-11016 ) were applied at 1:500 for 1 hr at RT.  After 
several washes in PBS, the specimens were mounted in CitiFluor (Sigma) and 
viewed under a Bio-Rad Radiance 2100 Rainbow confocal microscope.   
  
2.6 Animals 
Male NMRI mice bred in house were used at 20–30 g BW, adult male C57/BL6J 
mice of similar BW weight range were from Taconic labs. All animals were housed 
under standard laboratory conditions (24 ± 2 ºC, 40–60% relative humidity), on a 12 
h light/dark cycle with light onset at 6:00 AM. The left ventricle of the heart from adult 
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 8 
NMRI or C57/BL6 mice was obtained after rapid decapitation/exsanguination. The 
excised tissues were briefly rinsed in ice-cold PBS, frozen on dry ice and stored 
at -80°C prior to further processing.  
 
2.7 Immunoblots 
For the analysis of the cells examined for cAMP production, batches of transfected 
cells were processed for immunoblotting. Cells were detached from the culture plates 
in ice-cold HBSS (Sigma H 6648) supplemented with 1 mM EDTA, centrifuged at 
1000 x g for 1 min at 4°C. The resulting cell-pellet was homogenized by trituration 
with a 1ml Gilson Microman pipette tip in homogenization buffer (0.5M NaCO3, pH11, 
containing 1 mM EDTA, 1 mM EGTA and 15µl/ml of protease inhibitor cocktail 
(Sigma, P8340).   This buffer enriches the membranes for integral membrane 
proteins by stripping non-integral interacting proteins [14-16]. The homogenate was 
centrifuged at 1000xg for 10 min at 4°C and the resultant supernatant was further 
centrifuged at 100,000 x g for 40 min in a Beckman mini ultracentrifuge at 4°C 
(Beckman Coulter Optima Max-XP).   The pellet was re-suspended in 50mM sodium 
phosphate buffer pH 7.2, containing 2% SDS (w/v), 5% 2-mercaptoethanol (v/v) and 
adjusted to 1mg/ml protein or lower depending on the anticipated AC9 concentration 
of the sample.   SDS-PAGE and blotting onto Immobilon-FL, PVDF membranes 
(Merck-Millipore) were carried out in a Phast-Gel apparatus as previously reported 
[9].  Blots were blocked by LiCor blocking solution at RT for 60 min, washed with 
PBS-0.1% Tween-20 and incubated overnight at 4°C with primary antibodies. These 
were i) affinity purified rabbit antibodies directed against the NH2-terminal region 
common in mouse and human AC9 [9], ii) affinity-purified rabbit or sheep antibodies 
directed against the final fifteen COOH-terminal amino acid residues of human AC9 
[9], iii) a rabbit antiserum directed against the C2b paralogue-specific domain of 
mouse AC9 [17] kindly supplied by Dr. Richard Premont – also see Fig. 1A. In some 
cases, the rabbit anti-NH2-terminal and the sheep anti-COOH terminus antibodies 
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 9 
were applied in combination. In blots from transient transfection studies, a mouse 
monoclonal antibody against N+K+-ATPAse (Millipore 05-369 | Anti-Na+/K+ ATPase 
α-1 Antibody, clone C464.6) was used at 1:2000 dilution as a housekeeping marker 
for the amount of plasma membranes present.  Following the exposure to primary 
antibodies, the blots were washed with PBS-0.1% Tween-20 for 5 x 5 min and 
reacted with the requisite secondary reagents, selected from: IRDye 680LT 
Conjugated Goat (polyclonal) Anti-Rabbit IgG (H+L) (LI-COR, 926-68021),  IRDye 
800CW Conjugated Goat (polyclonal) Anti-Mouse IgG (H+L) (LI-COR, 926-32210), 
IRDye® 680LT Donkey anti-Goat IgG (H + L), 0.1 mg (925-68024), IRDye® 800CW 
Donkey anti-Goat IgG (H + L), 0.1 mg (925-32214) and incubated under constant 
rotation at RT for 60 min.  Blots were washed with PBS-0.1% Tween-20, air-dried, 
and subsequently imaged with a LiCor Odyssey dual laser imager, using the LICOR 
ImageStudio 2.1.12. software. Immunoreactive band intensities were calculated after 
local background substraction and are given as arbitrary units.  The ratio of the 
intensities of the AC9 immunoreactive band over the Na+K+ATP-ase immunoreactive 
band for each group of transfected cells was calculated and used to standardize the 
levels of cAMP production in that group.  
 
Well-characterized human myocardial tissue samples from the anterior wall of the left 
ventricle were obtained from the Transplantation Biobank of the Heart and Vascular 
Center at Semmelweis University, Budapest, Hungary. Following institutional and 
national ethical committee approval and informed consent from organ donor family 
members or end-stage heart failure patients undergoing heart transplantation, 
myocardial tissue samples were surgically removed, immediately frozen in liquid 
nitrogen, and stored at -80°C. Human brain samples from the hippocampus and the 
anterior cingulate cortex were collected and stored frozen by M. Palkovits at the 
Human Brain Tissue Bank of the Semmelweis University, Budapest, Hungary.   
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Mouse and human tissue samples were homogenized from frozen in ice-cold 
carbonate based homogenization buffer with a Ultra-Turrax T-25 homogenizer by two 
1 min bursts at setting 7, and crude membranes for SDS-PAGE were prepared as 
described above for HEK293 cells .  
 
2.8 Data analysis  
In transient transfection studies, the amount of cAMP per well was divided by the 
amount of protein in the well. Agonist-evoked standardized cAMP was calculated as 
follows: the respective baseline cAMP levels measured in the presence of IBMX 
were substracted from the values obtained in the presence of agonist.  The 
corresponding values from the group expressing the pcDNA3.1 skeleton vector were 
substracted to eliminate the contribution of the endogenous cAMP production of the 
host cells. In the case of wild type AC9, this sometimes resulted in negative values at 
low concentrations of agonist.  The values of net cAMP production thus obtained 
were corrected for the level of AC9 protein expression by multiplying with the ratio of 
the intensities of the AC9 and Na+K+-ATPase immunoreactive bands relevant for the 
batch of transfection. In the case of COS-7 cells where the human 5-HT7A receptor 
was contransfected with the AC9 variants, the binding capacity for 3H-SB-269970 
was also taken into account — cAMP production was divided by the 3H-SB-269970  
binding capacity of the membranes. Data are reported as individual data points or 
mean±S.D. Each experimental condition was tested in at least two independent 
studies. Data analysis was carried out with GraphPad Prism v6. As the standard 
deviation of the cAMP data was proportional to the respective means the data were 
analysed after log transformation. Results from stably transfected cells and time 
course studies of transiently transfected cells were analysed by two-way ANOVA 
followed by Tukey’s test for multiple comparisons. Dose response curves for 5-HT in 
transient transfections were assayed in duplicate except for the basal (n=4) and the 
highest concentration of 5-HT (1µM) applied (n=3).  In these cases the cAMP 
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response to 1µM 5-HT was analysed as an index of the maximal response by 
Student’s t-test or one-way ANOVA followed by Dunnett’s post-hoc test as 
appropriate.  
 
2.9 Ethical declaration: All animal experimental protocols were approved by the 
Animal Care and Use Ethical Committee of Egis Pharmaceuticals PLC and complied 
with the Hungarian Law of Animal Care and Use (1998. XVIII). The Human Tissue 
Bank, Semmelweis University, Hungary is a member of the Brain Net II Europe 
consortium. All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and national research 
committee and with the 1964 Declaration of Helsinki and its later amendments. 
Ethical permission numbers: 6008/8/2002/ETT and 32/1992/TUKEB for HBTB; ETT 
TUKEB 7891/2012/EKU (119/PI/12.) and TUKEB 73/2005  for myocardial samples.   
 
 
 
3. RESULTS 
3.1 Auto-inhibition of AC9 by a short motif in the C2b domain 
Basal cAMP accumulation in HEK293 cells stably transfected with AC9 or 
AC9_Y1242 was studied in the presence of 0.5 mM IBMX. As shown in Fig. 2A, both 
cell lines containing AC9 had much higher unstimulated cAMP levels than cells 
expressing the pcDNA3.1 skeleton vector. HEK293 cells express endogenous ß2-
adrenergic receptors [18]. Accordingly, isoproterenol produced a robust increase of 
cAMP levels in the presence of 0.5 mM IBMX in cells stably transfected with the 
skeleton vector pcDNA3.1 (Fig 2B). However, cells stably expressing high levels of 
human AC9 [10] showed only marginal enhancement of the cAMP response to 
isoproterenol when compared with the response of the host cells containing 
pcDNA3.1. Removal of the isoform-specific C2b domain resulted in an isoproterenol-
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induced cAMP response that was several-fold greater than that observed in 
pcDNA3.1 cells (Fig. 2B). Similar data were obtained with PGE2 as the agonist (Fig. 
2C).  Immunostaining with NH2- and COOH-terminal directed antibodies showed no 
major differences in the cellular localization or the level of expression of wild type 
AC9 and AC9_Y1242 (Fig. 3) in HEK 293 cells.  Cell expressing the skeleton vector 
pcDNA3.1 showed no AC9 immunopositive reaction (Supplementary Fig 2). 
Immunoblots (Fig. 3B) showed the expected full-length AC9 immunoreactive band at 
around 170 K [9, 10], a minor band reactive with the COOH-terminal antibody was 
also detected at around 90 K. Anti-NH2-terminal antibody avidly detected AC9-Y1242 
as a protein of lower molecular weight than AC9 that gave no reaction with the anti-
COOH terminus antibody (Fig 3B).  No immunopositive protein bands were found in 
pcDNA3.1 containing cells (Supplementary Fig 3). 
In order to exclude modifications of cAMP metabolism arising from the long-term 
overexpression of AC9, the requisite AC9 expression plasmids were transiently 
transfected into HEK293 stably expressing 5-HT7A receptors. Transient transfection 
with AC9 or AC9_Y1242 had no significant effect on the levels of 5-HT7A receptors as 
determined by [3H]-SB269970 binding (data not shown).  Importantly, the marked 
enhancement of the agonist-evoked cAMP response upon removal of the C2b 
domain was also evident in this system (Fig. 4A). The effect of cell context on the 
apparent auto-inhibitory role of the C2b domain was tested in COS-7 cells co-
transfected with 5HT7A receptor cDNA and the requisite AC9 cDNAs. As shown in 
Fig. 4B, the pattern of the cAMP response to 5-HT in COS-7 cells was closely similar 
to that seen in HEK293 cells. Finally, these studies also showed that truncation at 
V1288 does not alter the response of AC9 to GsCR activation (Fig. 4A & B).  
 
In order to delineate the segment of the C2b domain required for auto-inhibition of 
the agonist-induced activation of AC9, further COOH-terminally truncated mutants 
(see Fig. 1B) of AC9 were tested. When compared with AC9 and AC9_Y1242, the 
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COOH-terminally truncated versions showed binary, all-or-none characteristics with 
respect to cAMP formation induced by 5-HT. Specifically, while AC9_D1276 yielded 
a cyclase that had a low cAMP response to 5-HT identical to that of full-length AC9 
(Fig. 5A&C), AC9_D1268 produced a cAMP response closely similar to that of 
AC9_Y1242 (Fig. 5B&D). The raw cAMP data of these studies are shown in 
Supplementary fig 5 and 6). We also compared the stimulation of AC9 with that of 
dfm_AC9, as the C2b domain of the latter has a completely different sequence at 
positions 1268-1276 (Fig. 1C). As shown in Fig. 6, the standardized cAMP response 
of dfm_AC9 to 5-HT was several-fold greater than that of AC9, resembling the 
properties of AC9_Y1242. 
 
Finally, we tested the effects of mutations placed in the purported autoinhibitory 
domain (residues 1268-1276) of full-length AC9 (Fig. 7A). Mutation of the SPTD motif 
to AAAA produced a cyclase that was stimulated by 5-HT to a greater degree than 
AC9, but not reaching the cAMP response of AC9_Y1242 (Fig. 7B). As S1273 is a 
potential phosphorylation site of prolyl-directed protein kinases, the mutation S1273A 
was also tested.  The effect was to significantly enhance the cAMP response to 5-
HT, although to a much smaller extent than that seen with AC9_C2a (Fig. 6B).  
 
 Taken together, our in transfecto experiments showed that the paralogue-specific 
C2b domain of AC9 exerts a marked auto-inhibitory effect on the activation of the 
enzyme by a variety of GsCRs. We have previously reported a COOH-terminally 
truncated species of AC9 in rat brain and AtT20 pituitary tumour cells [9, 10, 19]. As 
the COOH-terminus of AC9 is encoded by a single large exon from residues 957 to 
1353, and no signs of mRNA splicing or editing are apparent, we examined heart and 
brain tissue for signs of proteolytic alterations of AC9.  
 
3.2 Two main forms of AC9 in rodent and human heart 
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Interestingly, the main species of AC9 expressed in the left ventricle of mouse heart 
appeared COOH-terminally truncated as it failed to react with the COOH-terminally 
directed antibodies (Fig. 9 A & B) and was of lower molecular weight (≈130K) than 
the full-length AC9 observed in HEK293 cells (Fig 2 B). Full-length AC9 in mouse 
heart was barely detectable by an antibody raised against the entire C2b domain [17] 
that readily reacted with AC9_1267 transfected into HEK293 cells, but failed to detect 
AC9_Y1242, confirming its specificity towards the C2b domain (Fig 8D). This 
observation strongly suggests that the auto-inhibitory segment consisting of residues 
1268-1276 is missing from the 130K AC9 species in mouse heart. A more complex 
picture emerged when membranes from a healthy control and five failing human 
hearts obtained from heart transplant donor and recipient patients, respectively, were 
examined for AC9 immunoreactive bands (Fig. 9). Importantly, in three of the 
samples (Tx22, Tx24, Tx32), a distinct immunoreactive band migrating at ≈130K was 
detected by NH2-terminal but not COOH-terminal anti-AC9 (Fig. 9A&B).  This band 
co-migrated with the NH2-reactive AC9 band from mouse hearts (Fig. 9C). In one of 
these samples, (Tx24) a COOH-terminally reactive AC9 band was only barely 
detectable with any of the three antibodies (sheep or rabbit anti-COOH-terminal AC9, 
both affinity purified, rabbit anti-C2b). In order to exclude post-homogenization 
artefacts, two independent samples were processed from each heart with identical 
results.  
 
In adult post-mortem human hippocampus and anterior cingulate cortex a ≈160 K 
species of AC9, that consistently migrated below the ≈170 K band from heart, 
predominated. This band was COOH-terminally intact, as indicated by the reaction 
with the extreme COOH-terminal directed antibodies (Fig 9D).   The less intense 
lower mass bands obtained with the NH2-terminal antibody were not investigated 
further.  
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4. DISCUSSION 
 
The present study shows that the C2b isoform-specific domain of AC9 exerts a 
marked auto-inhibitory effect on the activation of the enzyme by GsCR. Moreover, in 
the absence of data supporting alternative splicing of AC9 mRNA encoding the 
COOH-terminal region AC9, the results from mouse, as well as human heart 
suggest, that proteolytic cleavage of the C2b domain may gate the activation of AC9 
in the heart by relieving the autoinhibitory effect.  
 
4.1 Auto-inhibition of AC9 in transfecto 
In transfecto, the stimulation of AC9 by endogenous receptors in HEK 293 cells was 
barely discernible. In contrast, robust activation occurred upon reducing the length of 
the C2b domain to residue D1267 or by Ala mutations of residues within the 1268-
1277 sequence.  Our analysis was restricted to studies in intact cells, thus the 
mechanistic underpinnings of the C2b effect and the kinetic parameters of auto-
inhibition remain to be explored. The whole cell approach is justified, as the auto-
inhibitory effect may not be faithfully translatable in a cell-free system e.g. see ref 
[20].  Moreover, the use of a PDE blocker likely distorted the quantitative 
relationships, but was technically unavoidable.  Nevertheless, it is clear from the data 
presented that, through residues 1268 to 1276, the isoform-specific C2b domain 
exerts a major inhibitory effect on the activation of AC9 by GsCR. Interestingly, the 
auto-inhibitory motif is in a segment of the C2b domain that is phylogenetically highly 
conserved in vertebrates (Supplementary Fig. 8). Within this motif, S1273 was shown 
to contribute to the auto-inhibitory effect. As S1273 is potentially phosphorylated by 
prolyl-directed kinases that are highly active in HEK293 cells [6, 21] it may well 
represent a cell context-specific element of the auto-inhibitory effect. 
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Auto-inhibition is a potentially important issue for the physiological control of tmAC. 
As the mature enzyme courses through the endoplasmic reticulum network, the 
cytoplasmic loops are in the correct orientation for activation, provided Mg2+ATP is 
present. It is currently hypothesized that the C1a-C2a complex is stable in vivo and 
stimulation of enzyme activity by Gs-GTP or the diterpene drug forskolin is by 
optimization of the catalytically active conformation of the heterodimer [22]. 
Alternatively, it is possible that the C1a-C2a complex is not abundant in vivo and its 
formation is enhanced by Gs or forskolin [23]. Taken together, the findings imply that 
one of the roles of the isoform-specific domains could be to prevent physiologically 
irrelevant activation of tmACs. Indeed, previous, largely biochemical studies in cell 
free systems have implicated the C1b [24] and the NH2-terminal [25] domains in the 
inhibitory control of AC6, and the C1b domain in the inhibition of AC7 [26].  Our 
studies are the first to show auto-inhibitory control of a tmAC by C2b, which is 
operational in intact cells.   
 
Soluble AC (sAC) has also been reported to contain an auto-inhibitory domain close 
to the COOH-terminal end of the C2 catalytic domain, reviewed in [27]. The primary 
sequence required for auto-inhibition of AC9 has no obvious resemblance to that 
identified in sAC [27]. Furthermore, the biological relevance of the auto-inhibition in 
sAC is unknown. 
 
 A side-product of our analysis is that it clearly differentiates a major functional 
characteristic of the dfm-AC9 clone [7] from that of full-length AC9: the former lacks 
the C2b auto-inhibitory sequence and consequently generates a dramatically 
enhanced cAMP response to GsCR activation when compared with AC9. There is a 
single gene for AC9 in both the mouse and the human genomes. Moreover, the 
exon_intron architecture of the mouse as well as the human AC9 genes is similar, in 
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that residues 957-1353 ( i.e. from the end of the TM2 domain through to the COOH-
terminus) to are encoded by a single, large exon. There are no apparent alternative 
mRNA splicing sites in this segment of the either the mouse or the human gene. In 
agreement, the mRNA analysis of mouse heart AC9 by RT-PCR failed to show 
evidence for mRNA splicing or editing (See Supplement section 1). Thus, the 
biological relevance of dfm-AC9, originally cloned from a commercial human cardiac 
cDNA library [7], requires further study.  
 
4.2 Limited proteolysis and AC9 
Auto-inhibition relieved by limited proteolysis is a well-known regulatory mechanism 
in proteins [28]. Activation of tmACs by proteolysis has been described in several 
earlier studies [29-32].  However, no clear biological relevance could be provided for 
these observations and none of them seems to have been followed up in the longer 
term.  
 
A COOH-terminally truncated ≈130 K form of AC9 appeared to be the predominant 
species of the enzyme in membranes prepared from rodent left ventricular heart 
tissue. It is likely, that the bulk of the enzyme is in the myocardium [33]. A similar 
AC9 form, that gave no reaction with antibodies directed against the COOH-
terminus, was previously detected in AtT20 mouse pituitary tumour cells [9, 19]. The 
lack of a reaction of the 130 K AC9 species with the anti-C2b serum that readily 
detected recombinantly expressed AC9_D1268 and AC9_D1276 indicates that the 
auto-inhibitory domain is not present in this form of the enzyme. This is consonant 
with a previous report of rat heart with the same antiserum [17]. However, at present, 
it cannot be fully ruled out, that the anti-C2b serum is not sensitive enough to detect 
physiological levels of AC9 with only a small part of the C2b domain present.  Full 
length, ≈170K, COOH-terminally intact AC9 could be also detected at low levels in 
mouse heart.  Similar, ≈130 K and ≈170 K AC9 NH2-terminal immunoreactive bands 
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were present in the six human samples tested.  In three of the samples (Tx22, 24 
and 32), the 130 K species appeared substantially more abundant than the 170 K 
one.  However, at present no correlation with the clinical data is apparent that would 
explain this finding (T. Radovits personal communication).  
 
As to which protease(s) may be involved in the cleavage of AC9 is currently a matter 
of speculation. Previously, we reported that AC9 was readily cleaved in hippocampal 
membranes by a Ca2+-dependent protease activity that was blocked by selective 
inhibitors of calpain [34].  Interestingly, no such activity could be discerned in HEK 
293 cells [34].  Further work is required to clarify the site(s) of cleavage in the 
enzyme and the proteases involved.  
 
4.3 Functional implications 
A plausible consequence of increased cAMP generation by COOH-terminally 
cleaved AC9 is the amplitude modulation, i.e. a quantitative aspect, of the cAMP 
response. Whilst protein kinase A is fully stimulated at 1µM cAMP, other effector 
systems modulated by cAMP such as exchange protein directly activated by cAMP 
(EPAC) and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels 
require greater than 10µM cAMP to be active, reviewed in refs. [3, 4, 35]. HCN 
channels are relevant as pacemaker channels regulating the frequency of action 
potentials in the heart [36] as well as the CNS [37]. EPACs are involved in cardiac 
remodelling processes [35, 38] in which Ca2+-activated proteases such calpains 
and/or caspases are thought to play a prominent role [39, 40].  Could proteolytic 
disinhibition of AC9 be the link between caspase/calpain activation and EPAC 
signalling leading to remodelling of the heart? In a yet further cardiac context, AC9 in 
myocardiocytes associates with the A-kinase anchoring protein yotiao, which also 
complexes KCNQ1 potassium ion channel subunits important for heart repolarization 
reviewed in ref. [33]. Genetic deletion of AC9 is mostly embryonic lethal [6, 41, 42], 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 20 
but a small fraction of AC9 null homozygotes survive [42, 43].  Examination of the 
cardiac function of these animals [43] showed that the cAMP-dependent 
phosphorylation of the heat-shock protein Hsp20 is compromised, raising the 
possibility that AC9 in the heart may have a cardioprotective role [44]. Taken 
together, switching of the responsiveness of AC9 via proteolysis in the C2b domain 
may determine the spectrum of intracellular cAMP effectors activated in a complex 
extracellular stimulus environment such as that seen in neuronal development or 
myocardial hypertrophy.    
 
In conclusion, the data presented here demonstrate a potent auto-inhibitory motif in 
the isoform-specific COOH-terminal C2b domain of AC9. Moreover, the existence of 
a COOH-terminally truncated species of AC9 in the heart raises the possibility that 
the auto-inhibitory effect is relieved by limited proteolysis. Further work is warranted 
to examine the latter issue.  
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8. LEGENDS TO THE FIGURES 
 
 
Figure 1.  Scheme of the protein/DNA sequences and antibodies relevant for this 
study A) The  classic scheme of AC9 structure spanning the plasma membrane.  The 
arrow indicates the site of the start of the isoform-specific C2B domain at Y1242. The 
scheme also shows the approximate sites of the epitopes of the primary antibodies 
used  in this study.   B) Single letter amino acid code of the C2b domain of human 
AC9, arrowheads highlight the COOH-terminal truncations tested in this study.  C) 
Detail of the human AC9 cDNA sequence highlighting the double frame-shift 
mutation in the dfm_AC9 clone (Genebank accession no. AF036927) resulting in a 
change of the COOH-terminal sequence of the C2b domain from position P1252. 
The amino acid sequence of the mouse AC9 C2b domain (Genebank accession no. 
Z50190) is shown in the top row. Note the near identity with human AC9 AJ1333123. 
 
Figure 2. Marked enhancement of stimulated cAMP formation upon deletion of 
the C2b domain of AC9 at residue Y1242.  Studies in HEK293 cells stably 
transfected with skeleton vector (pcDNA3.1), human AC9 (AC9) or AC9 with the C2b 
domain removed at the cDNA level (AC9_Y1242). A) Time-course of cAMP 
accumulation upon the addition of 0.5 mM IBMX at time 0. Two-way ANOVA (10, 54) 
F=46.16, gave significant interaction. Tukey’s post-hoc test showed that at all time 
points except 0 min, the levels of cAMP in the AC9 and AC9_Y1242 were 
significantly (P<0.001)  higher than in the pcDNA3.1 group. At 30 and 40 min the 
levels of cAMP in AC9_Y1242 cells were significantly higher (*** P<0.001) than in 
cells AC9 containing AC9. B) Effect of the activation of endogenous 2-adrenergic 
receptors by isoproterenol on cAMP production in the presence of 0.5 mM IBMX. 
Note marked enhancement of the cAMP response in AC9_Y1242 cells. 2-way 
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ANOVA gave significant interaction (8, 45) F=66 P<0.0001. Tukey’s multiple 
comparisons test: **** P<0.0001 vs. pcDNA3.1, as well as AC9 groups,  *P<0.05 vs. 
pcDNA3.1 C) Effect of the activation of endogenous of EP2-4 prostanoid receptors 
by PGE2. Note marked enhancement of the cAMP response in AC9_Y1242 cells. 2-
way ANOVA gave significant interaction (10, 54) F=105.5 P<0.0001. Tukey’s multiple 
comparisons test: **** P<0.0001 vs. pcDNA3.1, as well as AC9 groups. Data are 
mean±S.D. n=4, and are representative of at least two independent experiments 
giving similar results.   
 
Figure 3.  Immunodetection for AC9 and AC9_Y1242 reveals no major 
differences in the distribution of the proteins in HEK293 cells. A) Stably 
transfected HEK293 cells were co-stained with affinity-purified primary rabbit (green) 
and sheep (red) antibodies directed against NH2- and anti-COOH-terminal of human 
AC9, respectively. Note close proximity of the immunoreactivity to the  plasma 
membrane and the absence of COOH-terminal staining cells expressing AC9_C2a.  
The bars represent 20 µm.  B)  Immunoblots of cell homogenates of HEK293 cells 
stably expressing  human AC9 (lanes 1 and 2) or AC9_Y1242  (lanes 3 and 4). Blots 
were reacted with affinity-purified primary rabbit (red) and sheep (green) antibodies 
directed against the NH2-terminal region and the COOH-terminus of human AC9, 
respectively.   
 
Figure 4.  The inhibitory effect of the C2b domain is independent of cell 
context.  A) Effect of serotonin (5-HT) on cAMP accumulation in HEK293 cells stably 
expressing 5-HT7A receptors and transiently transfected with AC9. Note the markedly 
enhanced response by AC9_Y1242 and that by AC9 truncated at residue V1288 
(AC9_V1288) did not differ from that of wild-type AC9.  Individual data points are 
shown. Inset: cAMP response at 1µM 5-HT, one-way ANOVA, F (2, 6) = 19.72, P = 
0.0023, ** P<0.01 vs. AC9, Dunnett’s test for multiple comparisons.  Geometric 
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means, the bars represent S.D. B) Similar results were obtained in COS 7 cells co-
transfected  with 5-HT7A receptors and the requisite AC9 variants. Individual data 
points are shown. Inset: cAMP response at 1µM 5-HT, one-way ANOVA F (2, 6) = 
52.34, P = 0.0002, *** P<0.001 vs. AC9, Dunnett’s test for multiple comparisons.  
Geometric means, the bars represent S.D.  Data are representative of two 
independent experiments.  
 
Figure 5.   Comparison of the properties of AC9_D1276  and AC_D1267 shows 
an  all-or-none type inhibitory effect of residues 1268-1277 (GSIGRSPTD).  A) 
AC9_D1276: Time-course of cAMP production evoked by 15 nM 5-HT. Data are 
means ± S.D. n=3 /point. Two- way ANOVA  gave significant interaction, F (12, 41) = 
214.4, P < 0.0001, **** P<0.0001 vs. AC9 as well as AC9_D1276, Tukey’s test for 
multiple comparisons.   B) AC9_D1267: Time-course of cAMP production evoked by 
15 nM 5-HT. Data are means ± S.D. n=3 /point. Two- way ANOVA gave significant 
interaction, F (12, 42)=23.16, P < 0.0001 , **** P<0.0001 vs. AC9. 
C) AC9_D1276: cAMP responses evoked by 5-HT, at 15 min after addition of the 
agonist. Individual data points are shown. Inset: cAMP response at 1µM 5-HT, one-
way ANOVA, F (2, 6) = 84.29, P < 0.0001, , *** P<0.001 vs. AC9, Dunnett’s test for 
multiple comparisons.  Geometric means, the bars represent S.D.  D)  AC9_D1267: 
cAMP responses evoked by 5-HT, at 15 min after addition of the agonist.  Individual 
data points are shown. Inset: cAMP response at 1µM 5-HT, one-way ANOVA,  F (2, 
6) = 422.1, P < 0.0001, **** P<0.0001 vs. AC9, Dunnett’s test for multiple 
comparisons.  Geometric means, the bars represent S.D. Data shown are 
representative of two independent experiments.  Note all-or-none type effect of the 
deletion of residues 1268-1277 on the 5-HT-induced cAMP response. 
 
Figure 6.  The double frame-shift mutant human AC9 (dfm-AC9) has properties 
similar to AC9_Y1242. The 5-HT-evoked cAMP response attributable to dfm_AC9 is 
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comparable to that seen with AC9_Y1242.  Individual data points are shown, 
representative of two independent experiments.  Inset: cAMP response at 1µM 5-HT, 
*** P<0.001, Student’s t-test. Data are representative of two independent 
experiments.   
 
Figure 7.  Mutations of the purported auto-inhibitory segment in full-length AC9 
partially mimic the effects of COOH-terminal deletion.  A) The site of the 
mutations within positions 1268-1277.  B) The effects of the mutations on cAMP 
production evoked by 5-HT at 15 min after the addition of the agonist. Data are 
means ± S.D. n=3/point.  Inset: cAMP response at 1µM 5-HT, one-way ANOVA,  F 
(3, 12) = 29.30, P < 0.0001, * P<0.05, *** P<0.001, **** P<0.0001 vs. AC9, Dunnett’s 
test for multiple comparisons.  Geometric means, the bars represent S.D. Data are 
representative of at least two independent experiments.  
 
Figure 8.  A COOH-terminally truncated species of AC9 in mouse heart. 
Immunoblots of crude membranes prepared from the left ventricle of the heart of 
C57/Bl6 male mice were reacted with affinity-purified primary rabbit (A) and sheep 
(B) antibodies directed against the NH2-terminal region and COOH-terminus of 
human AC9, respectively.  Note faint COOH-terminal reactive band in mouse heart. 
C) The same samples analyzed with an antiserum raised against the entire C2b 
region of AC9 [17]. Note the lack of reaction with the relatively abundant ≈130K band 
detected by anti-NH2-terminal antibodies. D) Partial characterization of the anti-C2b 
serum: immunoblots of crude membranes from HEK293 cells over-expressing 
AC9_D1267 (lane 1) AC9_D1276 (lane 2 ), full-length AC9 (lane 3) and AC9_Y1242 
(lane 4). Note lack of reaction with AC9_Y1242, confirming the specificity of the 
antiserum for the C2b domain.  
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Figure 9. Presence of COOH-terminally truncated AC9 in human heart.  A) 
Healthy control (HD) and failing (TX22-32) human hearts from transplant patients 
with different pathoaetiologies (TX22: myocarditis, TX23: restrictive cardiomyopathy, 
TX24: hypertrophic obstructive cardiomyopathy, TX31: ischemic heart disease, 
TX32: collagenosis) reacted with affinity-purified primary rabbit antibodies directed 
against the NH2-terminal region of AC9. Note the presence of a  ≈130 K AC9 species 
in all samples and the resolution of the ≈170 K band into a doublet in samples TX22 
and Tx23.  B)  Immunoblots of the same samples reacted with affinity-purified 
primary rabbit antibodies directed against the COOH-terminus of human AC9.  Note 
barely discernible ≈170 K band in sample Tx24. C) Samples from male mouse 
(C57/BL6, NMRI) and human hearts (Tx 23 and 24) reacted with affinity-purified 
primary rabbit antibodies directed against the NH2-terminal region of AC9. Note close 
similarity in Rf for the ≈130 K AC9 species from mouse and human hearts.  The full-
length ≈170 K  AC9 band was from HEK293 (AC9.1) cells stably transfected with 
human AC9. D) Immunoblot of human hippocampus (Hip) and anterior cingulate 
cortex (Cing) reacted with with affinity-purified primary rabbit antibodies directed 
against the NH2-terminal region of AC9 (left panel) and affinity-purified sheep 
antibodies directed against the COOH-terminus of human AC9 (right panel).  
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SUPPLEMENTARY DATA 
Auto-inhibition of adenylyl cyclase 9 (AC9) by an isoform-specific motif in the 
carboxyl-terminal region.     Pálvölgyi et al., Cellular Signalling. 
1.0  Examination of the C2b domain sequence of mouse AC9 mRNA derived from different 
tissues 
There are  two reference sequences of m. musculus AC9 mRNA that were derived from 
genomic mapping of  the mouse genome. Variant  1: Accession no. NM_009624 and 
Variant 2 Accession no.  NM_001291910.  
With respect to the latter  “...variant (2) differs in the 5' UTR, lacks a portion of the 5' 
coding region, and initiates translation initiation at a downstream start codon, compared to 
variant 1. The encoded protein (isoform 2), has a shorter N-terminus than isoform 1.” 
Variant 1 is predicted to be comprised of 11, variant 2 from 12 exons.   Significantly, the 
respective last exons in the two variants are identical and encode the COOH-terminal of 
the protein from the end of TM2 through C2a to C2b (see Fig. 1A of main article for 
nomenclature), from residue 957 to 1353. No potential mRNA splicing sites are apparent in 
the gene sequence.   Similar considerations apply to the human AC9 gene (ADCY9, 
NG_011434.1).                 
Total RNA was prepared from frozen adult mouse (C57Bl/6J) hippocampus, brain cortex, 
and heart tissue by extraction with TRIzol/chloroform (Invitrogen) as per the manufacturers 
instructions. The isolation was continued by Qiagen RNeasy Kit with DNaseI treatment of 
samples (On Column DNase I Digestion Set, Sigma). The quality of the RNA preparation 
was assessed by gel electrophoresis on an Agilent Bioanalyzer 2100. The synthesis of 
cDNA was performed with Revert Aid First Strand cDNA Synthesis Kit (Fermentas) 
according to the manufacturer’s description using 100 ng of each total RNA samples and 
oligo dT primers. Thereafter specific oligonucleotides were used to amplify  by PCR the 
coding region of exon 11 of mouse AC9 (forward1, forward2, reverse1, see Supplementary 
Fig 1).  
 
Supplementary Figure 1. Schematic summary of the analysis of mouse tissue AC9 mRNA by RT-PCR. 
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Table1. Mouse AC9 specific PCR primers (on the basis of NM_009624) 
forward1 GGTTCAACTTCAAGCTCAGGGTCGGCT exon11 (4239-4265 bp) 
forward2 GTCAGGACAGTTCCATTGTGATG exon9-10 (3585-3607 bp) 
forward3 GTTATGACTTTGACTACCGAGGG exon11 (4425-4447 bp) used for 
direct PCR product sequencing 
reverse1 CTAGATAGCACAACAGCCTATCGAC exon11 after stop codon (4908-
4884 bp) 
 	
Supplementary	Figure	1	
The PCR reaction was performed with Phusion High Fidelity DNA polymerase (Thermo 
Scientific) and was run as follows: 95 ºC for 5 min, followed by 33 cycles (95 ºC for 1 min, 
62 ºC for 40 sec and 72 ºC for 25/45 sec) and a final extension step (72 ºC for 3 min). The 
PCR products (forward1-reverse: 670 bp, forward2-reverse: 1324 bp, see Supplementary 
Figs.1 and 2) were purified with the QIAquick PCR Purification Kit according to the 
protocol and verified by agarose gel electrophoresis. The DNA sequence was determined 
directly from the two PCR products in each sample with the gene-specific forward 3 and 
the reverse1 primer (Suppl. Fig 1). In addition, both PCR products obtained from heart 
tissue were subcloned into the pJET1.2 plasmid (Thermo Scientific) and the sequence of 
the amplified cDNA products (3-3 clones of each type) were determined using the 
standard pJET reverse and forward sequencing primers. The sequencing data of each 
sample were analyzed by assembling with the mRNA reference sequence (NM_009624) 
using Geneious software. DNA sequencing was carried out at Biomi Ltd, Gödöllő, 
Hungary. 
 
Supplementary Figure 2.  RT-PCR  for AC9 mRNA in mouse cerebral cortex, hippocampus (Hippo) 
and the left ventricle of the heart.  Lane 1 : Primer Forward 1 and Reverse 1, Lane 2 : Primer Forward 
2 and Reverse 1 Lane 3: Control for contaminating DNA in the RNA sample. Note expected products 
of 670 and 1324  bp in all three tissues.  
The sequences of the two PCR products (Supplementary Fig. 2) were indetical to the 
reference mRNA sequence by direct sequencing and also after subcloning. One of the 
clones of the short PCR product had a single nucletide  change from G to A at nucleotide 
(bp. 4337), which would result in a valine to isoleucine change at position 1191 at the 
protein level.  Whether or not this is the result of DNA editing remains to be determined.  
However, it would not impact the immunoreaction with the either of the Anti-AC9 COOH-
terminal antibodies used  in this  study.  
There is a single gene for AC9 in both the mouse and the human genomes. Moreover, the 
exon_intron architecture of the mouse as well as the human AC9 genes is similar, in that 
residues 957-1353 ( i.e. from the end of the TM2 domain through to the COOH-terminus) 
are encoded by a single, large exon. There are no apparent alternative mRNA splicing 
sites in this segment of either the mouse or the human gene. In agreement, we found no 
evidence for alternative C-terminal transcript variants of mouse AC9 that could explain the 
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Supplementary	Figure	2	
presence of a COOH-terminally truncated AC9 protein in heart tissue. These findings are 
consonant with the computerized predictions derived from the sequence of exon 11 of the 
mouse gene as detailed at https://www.ncbi.nlm.nih.gov/nuccore/NM_009624.  
With respect to exon 11, the same considerations apply to the human ADCY9 gene as to 
the mouse - https://www.ncbi.nlm.nih.gov/nuccore/NM_001116.3. 
 
 
2.0 Verification of anti-AC9 antibodies in HEK293 cells expressing the skeleton 
vector pcDNA3.1. 
  
 
Supplementary Fig. 3. HEK293 cells stably expressing pcDNA3.1 were processed for immunostaining 
as detailed in section 2.5 of the article.  Note the lack of meaningful reaction with either affinity-purified 
rabbit anti-AC9_NH2-terminal region (NH2, green) or affinity-purified anti-AC9_COOH-terminus (COOH, red) 
antibodies. The Merge panel includes the blue channel images resulting from staining with DAPI to reveal 
the cell nuclei. The bars represent 20µm. In contrast, the same antibodies produced intense labeling of 
HEK239 cells stably expressing human AC9 or AC9_Y1242.  (see Fig. 2 of main paper). The anti-C2b rabbit 
serum received from R. Premont also failed to stain HEK293 cells expressing the skeleton vector (not 
shown).  
 
Supplementary Fig. 4. Immunoblots of crude membranes prepared from HEK293 cells stably 
expressing 5-HT7A receptors and transfected with pcDNA3.1 or human AC9 reacted with affinity-
purified rabbit anti-AC9 NH2-terminal region antibodies.  Note the absence of  AC9 immunostaining in 
cells transfected the skeleton vector pcDNA3.1.  
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3.0  Raw cAMP data corresponding to Fig 4.and Fig 5. of the main paper.   
 
Supplementary Fig. 5 (corresponding to Fig. 4 of main paper) 
A) HEK293 cells stably expressing 5-HT7A receptors were transfected with pcDNA3.1, AC9, AC9_Y1242, 
AC9_V1288.  The protocol for cAMP production in the presence of IBMX is described in section 2.3. B) 
COS-7 cells were co-transfected with the human 5-HT7A receptor and pcDNA3.1, AC9, AC9_Y1242 or 
AC9_V1288. cAMP production in response to 5-HT was assessed as for HEK293 cells.  Individual data 
points are shown. 
 
Supplementary Fig. 6 (corresponding to Fig. 5 of the main paper) 
A &B) Time-course of cAMP production evoked by 15 nM 5-HT. Data are means±S.D. C&D)  cAMP 
responses evoked by 5-HT, at 15 min after addition of the agonist.  Note all-or-none type effect of the 
deletion of residues 1268-1277 on the 5-HT-induced cAMP response. Individual data points are shown. 
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4.0 The auto-inhibitory motif is in a phylogenetically highly conserved segment of 
the C2b domain.  
 
Supplementary Figure 7 Alignments of the C2b domain of AC9 of selected vertebrate species.  
Sequences that spanned most of the human AC9 COOH-terminal domain were selected.  AC9 from further 
experimentally notable species such as zebrafish (Danio rerio) and Xenopus laevis, but for which the 
available sequences are much shorter, also show 100% conservation of the auto-inhibitory motif. Alignments 
were generated by the Clustal Omega server of the European Bioinformatics Institute, Hinxton, Cambridge, 
U.K. 
 
  
XM_006897431.1 Elephantulus edwardii (Cape elephant shrew)
XM_022752346.1 Seriola dumerili (greater amberjack)
BC136658.1 homo sapiens
Z50190.1 mus musculus
XM_005306178.3 Chrysemys picta belli (Western painted turtle)     
XM_009513803.1 Phalacrocorax carbo  (cormorant) 
XM_010578353.1 Haliaeetus leucocephalus (bald eagle)
XM_006897431.1      MKTYLYPKCTDSGLVPQHQLSISPDIRVQVDGSIGRSPTDEIANLVPSVQTSDS------ 54
XM_022752346.1      MKTYLYPKCTDNGVVPQHQLSISPDIRVQVDGSIGRSPTDEIANLVPSAQNADKTSLGSE 60
BC136658.1          MKTYLYPKCTDHRVIPQHQLSISPDIRVQVDGSIGRSPTDEIANLVPSVQYVDKTSLGSD 60
Z50190.1            MKTYLYPKCTDNGVVPQHQLSISPDIRVQVDGSIGRSPTDEIANLVPSVQYSDKASLGSD 60
XM_005306178.3      MKTYLYPKCMDNGVVPHHQLSISPDIRVQVDGSIGRSPTDEIANLVPSVQNSDKTSQGSD 60
XM_009513803.1      MKTYLYPKCMDNGIVPHHQLSISPDIRVQVDGSIGRSPTDEIANLVPSVQNSDKIAHGTD 60
XM_010578353.1      MKTYLYPKCMDNGIVPHHQLSISPDIRVQVDGSIGRSPTDEIANLVPSVQNSDKIAHGTD 60
                    ********* *  ::*:*******************************.*  *.      
XM_006897431.1      -SPQARDAYASSQRPRREPVRAEERPLFSKAIERSDGEDTGLEDTNELTKLNTTKAM--- 110
XM_022752346.1      NNAQAKDTHVSSKRLWKEPVKAEERCRFGKAIEKSDCEEMGMEEANELTKLNVSKSMPSA… 120
BC136658.1          SSTQAKDAHLSPKRPWKEPVKAEERGRFGKAIEKDDCDETGIEEANELTKLNVSKSV--- 117
Z50190.1            DSTQAKEAHLSSKRSWREPVKAEERFPFGKAIEKDSCEDIGVEEASELSKLNVSKSV--- 117
XM_005306178.3      NNLEPKDMLPSYKKLQKESLKAEDRCRFGKAV-KNDCEEAETEEVNELTKLNISKSV--- 116
XM_009513803.1      N-SETRDIHPSTKKLQKDAVQAEERCRFGKATEKTGCEEAGTEEVNELTKLNISKSV--- 116
XM_010578353.1      N-SETKDILPSAKKLQKDAVKAEERCRFGKAAEKTDCEEMGTEEVNELTKLNISKSV--- 116
                       : ::   * ::  :: ::**:*  *.**  : . ::   *:..**:*** :*::   
